AxoGen (NASDAQ:AXGN) Director Paul Thomas Sells 21,399 Shares

AxoGen, Inc. (NASDAQ:AXGN) Director Paul Thomas sold 21,399 shares of AxoGen stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $29.61, for a total transaction of $633,624.39. Following the completion of the transaction, the director owned 13,528 shares of the company’s stock, valued at $400,564.08. The trade was a 61.27% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

AxoGen Stock Performance

NASDAQ AXGN opened at $30.01 on Thursday. The firm has a market cap of $1.38 billion, a P/E ratio of -600.20 and a beta of 1.06. The company has a quick ratio of 2.64, a current ratio of 4.09 and a debt-to-equity ratio of 0.54. The company’s 50 day moving average is $22.81 and its 200-day moving average is $16.68. AxoGen, Inc. has a 12-month low of $9.22 and a 12-month high of $34.24.

AxoGen (NASDAQ:AXGN) last released its quarterly earnings data on Wednesday, October 29th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.09 by $0.03. The company had revenue of $60.08 million for the quarter, compared to analyst estimates of $56.90 million. AxoGen had a negative return on equity of 1.90% and a negative net margin of 0.98%. Sell-side analysts predict that AxoGen, Inc. will post -0.29 earnings per share for the current year.

Hedge Funds Weigh In On AxoGen

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. First Light Asset Management LLC increased its holdings in shares of AxoGen by 28.2% in the 3rd quarter. First Light Asset Management LLC now owns 5,805,730 shares of the medical equipment provider’s stock worth $103,574,000 after buying an additional 1,276,487 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of AxoGen by 4.6% during the 1st quarter. Vanguard Group Inc. now owns 2,538,607 shares of the medical equipment provider’s stock worth $46,964,000 after acquiring an additional 112,679 shares during the last quarter. ArrowMark Colorado Holdings LLC grew its position in AxoGen by 20.4% in the third quarter. ArrowMark Colorado Holdings LLC now owns 1,958,406 shares of the medical equipment provider’s stock worth $34,938,000 after acquiring an additional 332,498 shares in the last quarter. Balyasny Asset Management L.P. increased its stake in AxoGen by 183.9% in the second quarter. Balyasny Asset Management L.P. now owns 1,931,158 shares of the medical equipment provider’s stock valued at $20,953,000 after acquiring an additional 1,250,968 shares during the last quarter. Finally, Wasatch Advisors LP raised its position in AxoGen by 14.3% during the third quarter. Wasatch Advisors LP now owns 1,639,351 shares of the medical equipment provider’s stock valued at $29,246,000 after purchasing an additional 205,569 shares in the last quarter. Hedge funds and other institutional investors own 80.29% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Citigroup restated a “market outperform” rating on shares of AxoGen in a research report on Thursday, October 30th. Canaccord Genuity Group increased their target price on shares of AxoGen from $27.00 to $37.00 and gave the stock a “buy” rating in a research note on Friday, December 5th. Lake Street Capital raised their price target on shares of AxoGen from $30.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, December 4th. Citizens Jmp boosted their price target on shares of AxoGen from $26.00 to $34.00 and gave the company a “market outperform” rating in a research report on Thursday, October 30th. Finally, Jefferies Financial Group upped their price target on shares of AxoGen from $29.00 to $36.00 and gave the stock a “buy” rating in a report on Thursday, December 4th. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $35.56.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.